RxDoctor Payments Data

Todd Bromberg

Neurology · Jenkintown, PANPI 1174740419

Payments from drug & device makers

$89,413in general payments, 2019–2025

Across 639 payments — averaging $139.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$67K
  • Saluda Medical Americas, Inc.$9K
  • Boston Scientific$5K
  • Abbott$1K
  • Collegium Pharmaceutical, Inc.$1K
  • AbbVie$1K
  • plus $4K from 41 others
$339in research payments, 2019–2025

Across 4 payments — averaging $84.77 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Saluda Medical Americas, Inc.$339

What the payments were for

  • Consulting fees$8,20013%
  • Speaking & faculty fees$35,74057%
  • Travel & lodging$4,5727%
  • Food & beverage$14,71723%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$89,413 in reported general payments places this provider in the 85th percentile of 941 neurology providers in Pennsylvania.

See all neurology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$650,037
Medicare patients
548
Services billed
23,896

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate12$13,280
BelbucaBuprenorphine Hcl16$10,033
OxycontinOxycodone Hcl17$8,366
Xtampza ErOxycodone Myristate13$7,163
Gabapentin173$2,724
Lidocaine17$1,874
Fentanyl18$1,809
Oxycodone Hcl76$1,036
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen69$962
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen67$875
Tizanidine Hcl47$855
Tramadol Hcl89$736
Duloxetine Hcl50$642
Hydromorphone Hcl53$555
Pregabalin52$535

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er$1,139$17,19529 claims
PfizerNurtec Odt$188$13,28012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 941 neurology providers in Pennsylvania.

Other neurology in Jenkintown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →